Bexarotene-d4

Bexarotene-d4

• CAS Number: 2182068-00-2
• UNSPSC Description: Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].
• Target Antigen: Autophagy; RAR/RXR
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: CC1(C2=C(C(C)(CC1)C)C=C(C(C(C3=C([2H])C([2H])=C(C([2H])=C3[2H])C(O)=O)=C)=C2)C)C
• Molecular Weight: 352.50
• References & Citations: [1]Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.|[2]Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2.|[3]Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4(1):56-60.|[4]Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59(4):469-74.|[5]Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported